What is the process for coverage of cholinesterase inhibitors under the ADTI?
Coverage of cholinesterase inhibitors under the Alzheimer’s Drug Therapy Initiative is being conducted through PharmaCares Special Authority process. Two separate forms have been developed for the initiative initial coverage and renewal/switching coverage. Each form contains the assessment tools needed to determine if the patient qualifies to participate in the initiative. Initial coverage is granted for a 6-month period and the patient is reassessed at 6-month intervals. As long as they remain in the mild to moderate stages of Alzheimer’s disease and the prescriber determines that they are responding to treatment, coverage will continue. Pharmacists can check on IVR (interactive voice response) referring to the following DINs, to see if a patients coverage has been approved.
